RxDoctor Payments DataLook up a doctor →

Ulla Kristina Laakso, MD

Psychiatry · New York, NYNPI 1598841371

Payments from drug & device makers

$890,304in general payments, 2019–2025

Across 3,261 payments — averaging $273.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$198K
  • Alkermes, Inc.$196K
  • AbbVie$102K
  • Teva Pharmaceuticals USA, Inc.$82K
  • Vanda Pharmaceuticals Inc.$78K
  • Axsome Therapeutics, Inc.$48K
  • plus $187K from 30 others

What the payments were for

  • Consulting fees$74,8628%
  • Speaking & faculty fees$686,83977%
  • Travel & lodging$56,9996%
  • Food & beverage$71,1058%
  • Education$4920%
  • Gifts$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$890,304 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$169,988
Medicare patients
149
Services billed
1,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine43$385,415
LybalviOlanzapine/Samidorphan Malate120$187,227
RexultiBrexpiprazole34$60,324
Abilify MaintenaAripiprazole12$50,656
Seroquel XrQuetiapine Fumarate22$27,015
VraylarCariprazine Hcl20$23,355
CaplytaLumateperone Tosylate14$21,660
BelsomraSuvorexant38$15,955
Depakote ErDivalproex Sodium20$14,726
EquetroCarbamazepine26$10,003
Lurasidone Hcl20$9,702
Quetiapine Fumarate ErQuetiapine Fumarate201$8,930
QuviviqDaridorexant Hcl20$8,791
Divalproex Sodium ErDivalproex Sodium195$8,700
VyvanseLisdexamfetamine Dimesylate18$7,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$82,054$385,41543 claims
Alkermes, Inc.Lybalvi$195,935$187,227120 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$197,544$110,98046 claims
AbbVieVraylar$101,948$23,35520 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$21,595$21,66014 claims
MerckBelsomra$138$15,95538 claims
Validus Pharmaceuticals LLCEquetro$10,174$10,00326 claims
Idorsia Pharmaceuticals US IncQuviviq$16,782$8,79120 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$903$7,59118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →